Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company whose news flow centers on Alzheimer's disease drug development, pharmaceutical cannabinoids, and AI-enabled research. The company regularly reports updates on its lead asset, IGC-AD1, a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia, along with progress across its broader pipeline and AI platforms.
News about IGC Pharma often includes clinical trial milestones, such as enrollment progress and expansion of the CALMA study to new sites. For example, the company has highlighted reaching key enrollment thresholds and adding hybrid and virtual clinical sites like Dominion Medical Associates, part of Lightship's network, to improve access for patients in underserved and rural communities. These announcements provide insight into trial design, recruitment strategies, and geographic reach.
Investors and observers can also expect corporate and financial updates, including capital raises under an effective Form S-3 shelf registration statement, strategic divestitures of non-core assets, and changes to the company's fiscal year-end to align with the calendar year. SEC-reported events, such as registered direct offerings and asset sale closings, are frequently accompanied by press releases that explain how proceeds and transactions relate to IGC Pharma's clinical and research priorities.
Another recurring theme in IGC Pharma's news is AI and intellectual property developments. The company reports advances in its MINT-AD platform for Alzheimer's risk stratification and early detection, recognition from the National Institute on Aging for AI code quality, and new or allowed patents that expand its pharmaceutical cannabinoid portfolio, including microdose-based treatments for stuttering and Tourette's Syndrome.
In addition, IGC Pharma issues news on community and educational initiatives, such as sponsoring a caregiver-focused Alzheimer's book authored by neuropsychology experts. Together, these news items provide a view into the company's clinical progress, AI research, regulatory positioning, capital strategy, and engagement with the Alzheimer's community. Readers interested in IGC's stock and operations can use this news feed to follow trial updates, financing events, patent activity, and strategic decisions over time.
IGC Pharma (NYSE American: IGC) reported participation in the caregiver podcast Autumn Is Here to raise awareness of agitation in Alzheimer's and support patient engagement in its Phase 2 CALMA trial. The company said CALMA has reached approximately 80% enrollment and is advancing toward completion.
The episode featured IGC staff discussing recognition of agitation, differences from other behavioral symptoms, and the role of caregiver education in improving clinical-trial participation.
IGC Pharma (NYSE American: IGC) added Kerwin Medical Center in Dallas as a clinical site to its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease on April 22, 2026. The company reported approximately 80% enrollment and says the new site brings behavioral neurology expertise to support final recruitment and data quality.
The site's Principal Investigator is Dr. Alka Khera, M.D., and Kerwin Medical Center is part of the Pinnacle Network, bringing community-based research experience intended to aid patient access and retention as the trial advances toward enrollment completion.
IGC Pharma (NYSE American: IGC) received authorization in Colombia on April 9, 2026 to synthesize, formulate, and develop psilocybin at its Bogotá R&D facility under Fondo Nacional de Estupefacientes oversight.
The capability lets IGC evaluate psilocybin for neuropsychiatric symptoms (NPS) in dementia, including depression and anxiety, while its lead program IGC-AD1 (CALMA Phase 2) is ~80% enrolled and remains the company’s near-term priority.
IGC Pharma (NYSE:IGC) announced it has reached approximately 80% enrollment in the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease, with enrollment completion expected in mid-2026.
The randomized, double-blind, placebo-controlled study now enters its final recruitment phase, positioning the company to progress toward database lock and topline results that constitute a defined clinical catalyst.
IGC Pharma (NYSE American: IGC) said Ascendiant Capital Markets raised its equity research price target to $5.25 on April 8, 2026, citing clinical progress and expected catalysts in 2026.
The company noted its lead program, IGC-AD1, is in a Phase 2 CALMA trial for Alzheimer's-related agitation. IGC clarified analyst reports reflect analysts' views and that IGC is not responsible for analysts' content, accuracy, or timelines.
IGC Pharma (NYSE American: IGC) activated a new site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's dementia at Tandem Clinical Research in Metairie, Louisiana.
Principal Investigator Dr. Angela Traylor will lead the site. Enrollment is reported as over 70% complete, and the addition aims to expand geographic reach and patient access.
IGC Pharma (NYSE American:IGC) announced a 12-part national media partnership with New to The Street to expand investor awareness across institutional and retail audiences. The campaign includes long-form televised interviews, national TV commercial distribution, digital amplification to a combined 4.45 million YouTube subscribers, and outdoor billboards in Times Square and the NYC Financial District.
The company said the multi-channel effort will run as a coordinated series of placements and curated investor events designed to raise visibility while the company remains focused on disciplined clinical execution and scientific development.
IGC Pharma (NYSE:IGC)/b) filed its Form 10-KT on March 19, 2026 for the nine months ended , reflecting a fiscal year change to December year-end.
Key points: Phase 2 CALMA enrollment surpassed 70%; net loss improved by $1.8M to $4.1M; $2.7M divestiture yielded ~$1.1M non-cash profit; R&D rose 48% to $4.0M; revenue was $869k. The company highlighted U.S. patents for IGC-AD1 formulation and a microdose cannabinoid, positive preclinical in-vitro data, AI awards, and plans to complete CALMA enrollment and pursue partnerships and AI monetization in FYE 2026.
IGC Pharma (NYSE:IGC) will demonstrate its Agentic Harmonization Assistant (AHA), an AI platform for automating harmonization and analysis of complex biomedical datasets, at ADPD 2026 in collaboration with the Alzheimer's Disease Data Initiative (ADDI).
AHA targets integration of clinical trial data, imaging, and other biomedical sources to reduce manual preparation time and support development of IGC-AD1 in the Phase 2 CALMA trial.
IGC Pharma (NYSE:IGC) announced on February 26, 2026 that it filed utility patent applications covering the architectural framework of its AI-based Agentic Harmonization Assistant (AHA). IGC says AHA standardizes heterogeneous Alzheimer's datasets; the company has harmonized 15 datasets and advanced AHA to a semi-final AI evaluation.
The filings aim to protect AHA's design and methodologies while IGC continues CALMA clinical trial work and plans additional AHA details at the upcoming ADPD conference.